Evidence map›Paper›PMID 31690351›Full record

ArticleJournal for immunotherapy of cancer2019

Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.

Minh Ngoc Duong, Efe Erdes, Michael Hebeisen, Nathalie Rufer

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. A pain from the nose to the head: neurological commitment during long COVID.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Strategies and rules for tuning TCR-derived therapy.Expert reviews in molecular medicine · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Minh Ngoc DuongDepartment of oncology UNIL CHUV, Lausanne University Hospital and University of Lausanne, CH-1066, Epalinges, Switzerland.
Efe ErdesDepartment of oncology UNIL CHUV, Lausanne University Hospital and University of Lausanne, CH-1066, Epalinges, Switzerland.
Michael HebeisenDepartment of oncology UNIL CHUV, Lausanne University Hospital and University of Lausanne, CH-1066, Epalinges, Switzerland. Michael.Hebeisen@unil.ch.
Nathalie RuferDepartment of oncology UNIL CHUV, Lausanne University Hospital and University of Lausanne, CH-1066, Epalinges, Switzerland. Nathalie.Rufer@unil.ch.ORCID 0000-0002-9871-6271
University of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAffinity-optimized T cell receptor (TCR)-engineered lymphocytes targeting tumor antigens can mediate potent antitumor responses in cancer patients, but also bear substantial risks for off-target toxicities. Most preclinical studies have focused on T cell responses to antigen-specific stimulation. In contrast, little is known on the regulation of T cell responsiveness through continuous TCR triggering and consequent tonic signaling. Here, we addressed the question whether increasing the TCR affinity can lead to chronic interactions occurring directly between TCRs and MHC-(self) molecules, which may modulate the overall functional potency of tumor-redirected CD8 T cells. For this purpose, we developed two complementary human CD8 T cell models (i.e. HLA-A2 knock-in and knock-out) engineered with incremental-affinity TCRs to the HLA-A2/NY-ESO-1 tumor antigen.

methodsThe impact of HLA-A2 recognition, depending on TCR affinity, was assessed at the levels of the TCR/CD3 complex, regulatory receptors, and signaling, under steady-state conditions and in kinetic studies. The quality of CD8 T cell responses was further evaluated by gene expression and multiplex cytokine profiling, as well as real-time quantitative cell killing, combined with co-culture assays.

resultsWe found that HLA-A2 per se (in absence of cognate peptide) can trigger chronic activation followed by a tolerance-like state of tumor-redirected CD8 T cells with increased-affinity TCRs. HLA-A2

conclusionsOur observations indicate that sustained interactions between affinity-increased TCR and self-MHC can directly adjust the functional potential of T cells, even in the absence of antigen-specific stimulation. The observed tolerance-like state depends on TCR affinity and has therefore potential implications for the design of affinity-improved TCRs for adoptive T cell therapy, as several engineered TCRs currently used in clinical trials share similar affinity properties.

Indexed as

Antigens, NeoplasmCD3 ComplexCD8-Positive T-LymphocytesCell Line, TumorCytotoxicity, ImmunologicGene ExpressionHLA-A2 AntigenHumansImmunophenotypingImmunotherapy, AdoptiveLymphocyte ActivationNeoplasmsProtein BindingReceptors, Antigen, T-CellReceptors, Chimeric AntigenSignal TransductionAntigens, NeoplasmCD3 ComplexHLA-A2 AntigenReceptors, Antigen, T-CellReceptors, Chimeric AntigenCD8 T cellsImmunotherapyNY-ESO-1 tumor antigenPreclinical studyReceptor signalingT cell activationT cell functionTCR affinity optimizationTCR/CD3 complex

Identifiers

PMID31690351
PMCPMC6833194
OpenAlexW2984577051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.